Trial Profile
A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in healthy adult subjects.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2016
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload; Myelodysplastic syndromes
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals Corporation
- 18 Mar 2016 New trial record